BidaskClub lowered shares of TESARO, Inc. (NASDAQ:TSRO) from a hold rating to a sell rating in a research report report published on Friday, June 30th.
Several other equities research analysts have also commented on the stock. Raymond James Financial, Inc. reaffirmed a market perform rating on shares of TESARO in a report on Tuesday, June 20th. Leerink Swann lowered their price target on shares of TESARO from $164.00 to $143.00 and set a market perform rating on the stock in a report on Tuesday, June 20th. Wells Fargo & Company reaffirmed an outperform rating and issued a $236.00 price target on shares of TESARO in a report on Tuesday, June 20th. Bank of America Corporation reaffirmed a buy rating and issued a $154.00 price target on shares of TESARO in a report on Tuesday, June 20th. Finally, Cowen and Company lowered their price target on shares of TESARO from $145.00 to $124.00 and set a market perform rating on the stock in a report on Monday, June 19th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $173.74.
Shares of TESARO (TSRO) traded up 5.88% during trading on Friday, reaching $134.15. The company had a trading volume of 691,737 shares. TESARO has a 1-year low of $83.26 and a 1-year high of $192.94. The stock’s market capitalization is $7.23 billion. The company’s 50 day moving average is $136.70 and its 200-day moving average is $151.09.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) EPS for the quarter, missing the consensus estimate of ($2.26) by $0.29. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $3.84 million. During the same period in the previous year, the company posted ($2.22) earnings per share. TESARO’s revenue for the quarter was up 909.8% compared to the same quarter last year. On average, equities research analysts anticipate that TESARO will post ($8.67) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/07/29/bidaskclub-downgrades-tesaro-inc-tsro-to-sell-updated-updated-updated.html.
In related news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the transaction, the vice president now owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 40.50% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. acquired a new stake in TESARO during the first quarter worth approximately $177,000. Fox Run Management L.L.C. acquired a new stake in TESARO during the second quarter worth approximately $224,000. World Asset Management Inc acquired a new stake in TESARO during the second quarter worth approximately $227,000. Private Capital Advisors Inc. acquired a new stake in TESARO during the second quarter worth approximately $232,000. Finally, Capstone Asset Management Co. acquired a new stake in TESARO during the second quarter worth approximately $238,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.